These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 20477865

  • 1. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
    Gay F, Vincent Rajkumar S, Falco P, Kumar S, Dispenzieri A, Petrucci MT, Gertz MA, Boccadoro M, Keith Stewart A, Palumbo A.
    Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
    Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA, MM-015 Investigators.
    N Engl J Med; 2012 May 10; 366(19):1759-69. PubMed ID: 22571200
    [Abstract] [Full Text] [Related]

  • 4. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
    Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omedè P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foà R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT, GIMEMA--Italian Multiple Myeloma Network.
    J Clin Oncol; 2007 Oct 01; 25(28):4459-65. PubMed ID: 17785703
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azaïs I, Decaux O, Garderet L, Mathiot C, Fontan J, Lafon I, Virion JM, Moreau P.
    J Clin Oncol; 2009 Aug 01; 27(22):3664-70. PubMed ID: 19451428
    [Abstract] [Full Text] [Related]

  • 6. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
    Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H, Aydogdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L.
    Eur J Haematol; 2011 Jan 01; 86(1):16-22. PubMed ID: 20942865
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J, Nicklasson L, Murthy A.
    J Med Econ; 2011 Jan 01; 14(6):690-7. PubMed ID: 21892856
    [Abstract] [Full Text] [Related]

  • 8. Autologous transplantation and maintenance therapy in multiple myeloma.
    Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omedé P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M.
    N Engl J Med; 2014 Sep 04; 371(10):895-905. PubMed ID: 25184862
    [Abstract] [Full Text] [Related]

  • 9. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
    Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV.
    Blood; 2010 Feb 18; 115(7):1343-50. PubMed ID: 20008302
    [Abstract] [Full Text] [Related]

  • 10. Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients.
    Falco P, Cavallo F, Larocca A, Rossi D, Guglielmelli T, Rocci A, Grasso M, Siez ML, De Paoli L, Oliva S, Molica S, Mina R, Gay F, Benevolo G, Musto P, Omedè P, Freilone R, Bringhen S, Carella AM, Gaidano G, Boccadoro M, Palumbo A.
    Leukemia; 2013 Mar 18; 27(3):695-701. PubMed ID: 22996335
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.
    Haematologica; 2005 Dec 18; 90(12):1650-4. PubMed ID: 16330438
    [Abstract] [Full Text] [Related]

  • 12. Frontline treatment of multiple myeloma in elderly patients.
    Moreau P, Hulin C, Facon T.
    Blood Rev; 2008 Nov 18; 22(6):303-9. PubMed ID: 18550234
    [Abstract] [Full Text] [Related]

  • 13. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A, Attal M, Roussel M.
    Clin Cancer Res; 2011 Mar 15; 17(6):1253-63. PubMed ID: 21411441
    [Abstract] [Full Text] [Related]

  • 14. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD, Multiple Myeloma (010) Study Investigators.
    N Engl J Med; 2007 Nov 22; 357(21):2123-32. PubMed ID: 18032762
    [Abstract] [Full Text] [Related]

  • 15. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec 22; 18(104):263-6. PubMed ID: 20025098
    [Abstract] [Full Text] [Related]

  • 16. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P.
    Semin Hematol; 2005 Oct 22; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [Abstract] [Full Text] [Related]

  • 17. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P.
    Lancet Haematol; 2020 Jun 22; 7(6):e456-e468. PubMed ID: 32359506
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
    Fouquet G, Tardy S, Demarquette H, Bonnet S, Gay J, Debarri H, Herbaux C, Guidez S, Michel J, Perrot A, Serrier C, Miljkovic D, Avet Loiseau H, Facon T, Hulin C, Leleu X.
    Cancer; 2013 Oct 15; 119(20):3680-6. PubMed ID: 23921945
    [Abstract] [Full Text] [Related]

  • 19. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.
    J Clin Oncol; 2010 Feb 10; 28(5):800-7. PubMed ID: 20048187
    [Abstract] [Full Text] [Related]

  • 20. Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.
    Ishak KJ, Caro JJ, Drayson MT, Dimopoulos M, Weber D, Augustson B, Child JA, Knight R, Iqbal G, Dunn J, Shearer A, Morgan G.
    Value Health; 2011 Feb 10; 14(5):672-8. PubMed ID: 21839405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.